Brand Stories
3 No-Brainer Artificial Intelligence (AI) Stocks to Buy on a Dip
The market has returned to its highs, along with many top artificial intelligence (AI) names. However, another market dip could always be around the corner.
Let’s look at three top AI stocks that have made strong runs that would be good buys on a pullback.
Image source: Getty Images.
1. Palantir
With a high valuation but attractive growth opportunities, Palantir Technologies (PLTR -0.34%) is a stock that would be attractive on a dip. The company has emerged as one of the market’s most compelling AI growth stories, and its momentum has been gaining speed.
In the first quarter, Palantir posted its seventh consecutive period of accelerating growth, with revenue up 39%. The rise is being led by its U.S. commercial segments, which saw sales jump 71% and the value of future deals soar 127%.
While there is a lot of talk about which company is building the best AI model, Palantir is focused on something far more practical: making AI useful. Its Artificial Intelligence Platform (AIP) uses AI models to help solve real-world problems.
AIP does this by gathering data and then connecting it to physical assets and operational workflows, allowing companies to make AI more useful. As a result, the platform is being used for a growing list of purposes, including hospitals monitoring for sepsis, insurers using it in their underwriting, and energy companies optimizing their pipeline infrastructure.
The company’s largest customer is the U.S. government, which is starting to embrace AI to become more efficient. Last quarter, Palantir’s government revenue climbed 45%.
The company also recently landed a major deal with NATO, expanding into international defense just as Europe ramps up military spending. That gives it three potential growth engines: domestic commercial enterprises, the U.S. government, and now the international public sector.
Yes, the stock is expensive by traditional metrics, but Palantir looks like it’s laying the groundwork to become one of the next megacaps. As such, any pullback could be a great buying opportunity.
2. Nvidia
Nvidia (NVDA -0.42%) has once again been helping lead the market higher. The company recently got good news when the Trump administration said the U.S. would ease chip export controls, allowing the company to resume selling its H20 chips to China. This will add billions in revenue.
Nvidia remains the undisputed champion of AI infrastructure, with its graphics processing units (GPUs) the backbone of this build-out due to their fast processing speeds. And the company has sped up its development cycle to ensure it remains on top.
Over the past two years, data center revenue has exploded from $4.3 billion to more than $39 billion — incredible growth for a company the size of Nvidia. It held a 92% share in the GPU market in the first quarter.
Its chips drive sales, but its secret weapon is its CUDA software. The company created the free platform in 2006 as a way to expand the use of GPUs beyond their original purpose of speeding up graphics in video games.
While it was slow to play out in other end markets, Nvidia smartly pushed CUDA into academia and research labs, where early AI research was being done. That led developers to build directly on CUDA, leading to a growing collection of tools and libraries designed to maximize GPU performance for AI workloads.
If shares of Nvidia dip, be ready to pounce. Data center spending continues to ramp up, and the company has a big opportunity in the automotive market, too, as autonomous and smart vehicles start to become more prevalent.
3. Microsoft
Another company that has seen its stock run up in price is Microsoft (MSFT -0.32%). It dominates the enterprise software space with its Microsoft 365 suite of worker productivity products and has one of the leading cloud computing companies in Azure.
The cloud remains the company’s fastest-growing business, with the unit producing revenue growth of 30% or more each of the past seven quarters. Azure revenue jumped 33% last quarter (35% in constant currency), with nearly half of that coming from AI services. Growth could have been even higher, but Microsoft has been hitting capacity constraints.
As such, it plans to ramp up capital expenditures (capex) in fiscal 2026 with a focus on adding GPUs and servers. It said those assets are more directly tied to AI revenue than buying the buildings that house them. That’s a smart move that should support continued cloud computing momentum.
Microsoft’s $10 billion investment in OpenAI gave it an early AI lead, especially with Azure initially being granted exclusive access to its leading large language models (LLMs). Companies continue to be attracted to OpenAI’s popular AI models, and Azure gives its customers direct access to them.
It has also embedded OpenAI’s models throughout its ecosystem to run its Copilot, which is gaining popularity with businesses. At $30 per enterprise user per month, it offers a lot of strong upside.
That said, the OpenAI partnership is getting complicated. The exclusivity deal is over, and the two sides are reportedly negotiating new terms as the AI provider looks to restructure. Still, Microsoft remains entitled to 49% of OpenAI Global’s profits up to a tenfold return on its investment — potentially a huge payday.
Microsoft remains in a strong long-term position. The stock’s recent run-up makes it an attractive candidate to buy on any pullback.
Brand Stories
This Artificial Intelligence Stock Has Beaten the Market in 9 of the Past 10 Years. And It’s On Track to Do It Again in 2025.
Investing in top growth stocks is a great way to achieve strong returns and potentially outperform the market as a whole. The S&P 500 is an index of the leading companies on the U.S. markets, and historically, it has risen by 10% per year, though that’s an average including up and down years. That return is not guaranteed, but at such a high rate, an investment would double after a little more than seven years.
One artificial intelligence (AI) stock that has routinely outperformed the broad index is Broadcom (AVGO -1.12%).
The semiconductor and infrastructure company has benefited from the growth in tech in recent years, and that has allowed it to outperform the market on a consistent basis. With strong gains once again so fare this year, is Broadcom still a great buy, or could it be due for a pullback?
Image source: Getty Images.
Broadcom has been a top growth stock over the past decade
Here’s a look at just how well Broadcom has performed over the previous 10 years, compared to the S&P 500.
Year | S&P 500 Return | AVGO Return |
---|---|---|
2024 | 23.31% | 107.69% |
2023 | 24.23% | 99.64% |
2022 | (19.44%) | (15.97%) |
2021 | 26.89% | 51.97% |
2020 | 16.26% | 38.55% |
2019 | 28.88% | 24.28% |
2018 | (6.24%) | (1.02%) |
2017 | 19.42% | 45.33% |
2016 | 9.54% | 21.78% |
2015 | (0.73%) | 44.30% |
Data source: YCharts.
What’s surprising is that the one year when the S&P 500 did better than Broadcom was 2019, when the index finished higher at nearly 29%, versus 24% gains for Broadcom.
The past doesn’t predict the future, but the tech stock’s terrific run can’t be ignored. In 10 years, shares of Broadcom have risen by more than 2,000%, while the S&P 500 has increased by around 200%.
Can Broadcom’s impressive gains continue?
As of the end of last week, Broadcom’s stock was up around 19% for the year, which was comfortably above the S&P 500’s returns of more than 6%. But with a valuation of around $1.3 trillion and Broadcom trading at 33 times its estimated future earnings (based on analyst estimates), it’s not a cheap stock to own.
The biggest risk is that the company relies heavily on demand from hyperscalers. These are big tech giants that have significant infrastructure needs related to tech and AI. If they scale back on their expenditures, that could significantly weigh on Broadcom’s results. The company estimates that its top five customers account for around 40% of its revenue.
The company’s revenue during the most recent reported period — which ended on May 4 — grew by a rate of 20% year over year, as its top line came in at just over $15 billion, while profits more than doubled, rising to nearly $5 billion.
If Broadcom can continue producing strong results such as these, it wouldn’t be surprising to see it outperform the market once again this year. Though that risk of hyperscalers cutting spending remains.
Is Broadcom stock a buy right now?
If you’re bullish on AI and expect there to be much more growth ahead, Broadcom can make for a compelling investment to simply buy and hold. But at the same time, it’s also important to consider the risks ahead, especially as tariffs and trade wars could impact growth in the tech sector in the near future.
Earlier this year, Broadcom’s stock was underperforming the S&P 500 due to the uncertainty in the markets. While that looks like a distant memory right now, investors should brace for a possible slowdown for the stock as it’s trading at an elevated valuation and it may be due for a decline. Its track record may be impressive, but that by no means guarantees it’ll always be a market-beating stock.
I’d hold off on buying shares of Broadcom only because the markets appear to be a bit too bullish right now, and with high expectations priced in, there’s a lot of downside risk that comes with owning the stock. Broadcom isn’t a bad buy, but I think there are better AI stocks to invest in today.
Brand Stories
AI in health care could save lives and money — but not yet

Imagine walking into your doctor’s office feeling sick – and rather than flipping through pages of your medical history or running tests that take days, your doctor instantly pulls together data from your health records, genetic profile and wearable devices to help decipher what’s wrong.
This kind of rapid diagnosis is one of the big promises of artificial intelligence for use in health care. Proponents of the technology say that over the coming decades, AI has the potential to save hundreds of thousands, even millions of lives.
What’s more, a 2023 study found that if the health care industry significantly increased its use of AI, up to US$360 billion annually could be saved.
WATCH: How artificial intelligence impacted our lives in 2024 and what’s next
But though artificial intelligence has become nearly ubiquitous, from smartphones to chatbots to self-driving cars, its impact on health care so far has been relatively low.
A 2024 American Medical Association survey found that 66% of U.S. physicians had used AI tools in some capacity, up from 38% in 2023. But most of it was for administrative or low-risk support. And although 43% of U.S. health care organizations had added or expanded AI use in 2024, many implementations are still exploratory, particularly when it comes to medical decisions and diagnoses.
I’m a professor and researcher who studies AI and health care analytics. I’ll try to explain why AI’s growth will be gradual, and how technical limitations and ethical concerns stand in the way of AI’s widespread adoption by the medical industry.
Inaccurate diagnoses, racial bias
Artificial intelligence excels at finding patterns in large sets of data. In medicine, these patterns could signal early signs of disease that a human physician might overlook – or indicate the best treatment option, based on how other patients with similar symptoms and backgrounds responded. Ultimately, this will lead to faster, more accurate diagnoses and more personalized care.
AI can also help hospitals run more efficiently by analyzing workflows, predicting staffing needs and scheduling surgeries so that precious resources, such as operating rooms, are used most effectively. By streamlining tasks that take hours of human effort, AI can let health care professionals focus more on direct patient care.
WATCH: What to know about an AI transcription tool that ‘hallucinates’ medical interactions
But for all its power, AI can make mistakes. Although these systems are trained on data from real patients, they can struggle when encountering something unusual, or when data doesn’t perfectly match the patient in front of them.
As a result, AI doesn’t always give an accurate diagnosis. This problem is called algorithmic drift – when AI systems perform well in controlled settings but lose accuracy in real-world situations.
Racial and ethnic bias is another issue. If data includes bias because it doesn’t include enough patients of certain racial or ethnic groups, then AI might give inaccurate recommendations for them, leading to misdiagnoses. Some evidence suggests this has already happened.
Humans and AI are beginning to work together at this Florida hospital.
Data-sharing concerns, unrealistic expectations
Health care systems are labyrinthian in their complexity. The prospect of integrating artificial intelligence into existing workflows is daunting; introducing a new technology like AI disrupts daily routines. Staff will need extra training to use AI tools effectively. Many hospitals, clinics and doctor’s offices simply don’t have the time, personnel, money or will to implement AI.
Also, many cutting-edge AI systems operate as opaque “black boxes.” They churn out recommendations, but even its developers might struggle to fully explain how. This opacity clashes with the needs of medicine, where decisions demand justification.
WATCH: As artificial intelligence rapidly advances, experts debate level of threat to humanity
But developers are often reluctant to disclose their proprietary algorithms or data sources, both to protect intellectual property and because the complexity can be hard to distill. The lack of transparency feeds skepticism among practitioners, which then slows regulatory approval and erodes trust in AI outputs. Many experts argue that transparency is not just an ethical nicety but a practical necessity for adoption in health care settings.
There are also privacy concerns; data sharing could threaten patient confidentiality. To train algorithms or make predictions, medical AI systems often require huge amounts of patient data. If not handled properly, AI could expose sensitive health information, whether through data breaches or unintended use of patient records.
For instance, a clinician using a cloud-based AI assistant to draft a note must ensure no unauthorized party can access that patient’s data. U.S. regulations such as the HIPAA law impose strict rules on health data sharing, which means AI developers need robust safeguards.
WATCH: How Russia is using artificial intelligence to interfere in election | PBS News
Privacy concerns also extend to patients’ trust: If people fear their medical data might be misused by an algorithm, they may be less forthcoming or even refuse AI-guided care.
The grand promise of AI is a formidable barrier in itself. Expectations are tremendous. AI is often portrayed as a magical solution that can diagnose any disease and revolutionize the health care industry overnight. Unrealistic assumptions like that often lead to disappointment. AI may not immediately deliver on its promises.
Finally, developing an AI system that works well involves a lot of trial and error. AI systems must go through rigorous testing to make certain they’re safe and effective. This takes years, and even after a system is approved, adjustments may be needed as it encounters new types of data and real-world situations.
AI could rapidly accelerate the discovery of new medications.
Incremental change
Today, hospitals are rapidly adopting AI scribes that listen during patient visits and automatically draft clinical notes, reducing paperwork and letting physicians spend more time with patients. Surveys show over 20% of physicians now use AI for writing progress notes or discharge summaries. AI is also becoming a quiet force in administrative work. Hospitals deploy AI chatbots to handle appointment scheduling, triage common patient questions and translate languages in real time.
READ MORE: AI and ‘recession-proof’ jobs: 4 tips for new job seekers
Clinical uses of AI exist but are more limited. At some hospitals, AI is a second eye for radiologists looking for early signs of disease. But physicians are still reluctant to hand decisions over to machines; only about 12% of them currently rely on AI for diagnostic help.
Suffice to say that health care’s transition to AI will be incremental. Emerging technologies need time to mature, and the short-term needs of health care still outweigh long-term gains. In the meantime, AI’s potential to treat millions and save trillions awaits.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Brand Stories
WATCH: President Trump announced $90B investment in AI: What this means for the DMV – WJLA
-
Mergers & Acquisitions1 week ago
Amazon weighs further investment in Anthropic to deepen AI alliance
-
Mergers & Acquisitions1 week ago
How Elon Musk’s rogue Grok chatbot became a cautionary AI tale
-
Mergers & Acquisitions1 week ago
UK crime agency arrests 4 people over cyber attacks on retailers
-
Brand Stories2 weeks ago
Voice AI Startup ElevenLabs Plans to Add Hubs Around the World
-
Asia Travel Pulse2 weeks ago
Looking For Adventure In Asia? Here Are 7 Epic Destinations You Need To Experience At Least Once – Zee News
-
AI in Travel2 weeks ago
‘Will AI take my job?’ A trip to a Beijing fortune-telling bar to see what lies ahead | China
-
Mergers & Acquisitions1 week ago
EU pushes ahead with AI code of practice
-
Mergers & Acquisitions2 weeks ago
ChatGPT — the last of the great romantics
-
Mergers & Acquisitions1 week ago
Humans must remain at the heart of the AI story
-
The Travel Revolution of Our Era1 month ago
CheQin.ai Redefines Hotel Booking with Zero-Commission Model
You must be logged in to post a comment Login